NEW YORK, NY / ACCESSWIRE / April 30, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) between August 14, 2014 and March 13, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information go to:

http://www.zlk.com/pslra-d/cemex?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) CEMEX executives had engaged in an unlawful bribery scheme in connection with the Company’s business dealings in Colombia; (ii) discovery of the foregoing conduct would likely subject the Company to heightened regulatory scrutiny and potential criminal sanctions; (iii) the Company lacked adequate internal controls over financial reporting; and (iv) as a result, CEMEX’s public statements were materially false and misleading at all relevant times.

If you suffered a loss in CEMEX you have until May 15, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 498038

NEW YORK, NY / ACCESSWIRE / April 30, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of WageWorks, Inc. (“WageWorks”) (NYSE: WAGE) between May 6, 2016 and March 1, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go to:

http://www.zlk.com/pslra-d/wageworks-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) there were material weaknesses in WageWorks’ systems of internal controls and that its practices and controls were ineffective; (2) WageWorks failed to adequately manage and assess risk relating to certain complex transactions, including certain government contracts; (3) WageWorks improperly recognized revenue thereby inflating its earnings and related financial metrics; and (4) as a result, WageWorks’ financial statements were materially false and misleading at all relevant times.

If you suffered a loss in WageWorks you have until May 8, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 498035

NEW YORK, NY / ACCESSWIRE / April 30, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of WageWorks, Inc. (NYSE: WAGE) who purchased shares between May 6, 2016 and March 1, 2018. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) there were material weaknesses in WageWorks’ systems of internal controls and that its practices and controls were ineffective; (2) WageWorks failed to adequately manage and assess risk relating to certain complex transactions, including certain government contracts; (3) WageWorks improperly recognized revenue thereby inflating its earnings and related financial metrics; and (4) as a result, WageWorks’ financial statements were materially false and misleading at all relevant times.

Shareholders have until May 8, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/wageworks-inc?wire=1.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 498030

NEW YORK, NY / ACCESSWIRE / April 30, 2018 / The following statement is being issued by Levi
& Korsinsky, LLP:

To: All persons or
entities who purchased or otherwise acquired securities of Henry Schein, Inc.
(“Henry Schein”) (NASDAQ: HSIC)
between March 7, 2013 and February 12,
2018. You are hereby
notified that a securities class action lawsuit has
been commenced in the United States District Court for the Eastern District of
New York. To get more information, go
to:

http://www.zlk.com/pslra-d/henry-schein-inc?wire=1

or contact Joseph E. Levi, Esq. either
via email at jlevi@levikorsinsky.com or by telephone
at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or
obligation to you.

The complaint alleges that, throughout
the Class Period, Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (1) Henry Schein was engaging in
unethical, anti-competitive behavior through agreements with Benco Dental
Supply Company and Patterson Companies, Inc., in violation of United States
antitrust laws; (2) Henry Schein engaged in such behavior, in part, to help
maintain profitability in a consolidating health care industry; (3) these
violations of U.S. antitrust laws would result in heightened scrutiny by the
federal government and a lawsuit filed by the Federal Trade Commission
(“FTC”); (4) Henry Schein failed to maintain adequate internal
controls; and (5) as a result, defendants’ statements about Henry Schein’s
business, operations, and prospects were materially false and misleading and/or
lacked a reasonable basis at all relevant times.

If you suffered a loss in
Henry Schein, you have until May 7, 2018
to request that the Court appoint you as lead plaintiff. Your ability to share
in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national
firm with offices in New York, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience representing investors
in securities litigation, and have recovered hundreds of millions of dollars
for aggrieved shareholders. Attorney advertising. Prior results do not
guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE:
Levi & Korsinsky, LLP

ReleaseID: 498029

NEW YORK, NY / ACCESSWIRE / April 30, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Akorn, Inc. (“Akorn”) (NASDAQ: AKRX) between March 1, 2017 and February 26, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Illinois. To get more information go to:

http://www.zlk.com/pslra-d/akorn-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s failure to comply with FDA data integrity requirements would jeopardize Fresenius’ acquisition of the Company; (2) the Company lacked effective internal controls over financial reporting; and (3) as a result, the Company’s financial statements were materially false and misleading at all relevant times.

If you suffered a loss in Akorn you have until May 7, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 498028

WEST LAFAYETTE, IN / ACCESSWIRE / April 30, 2018 / Bioanalytical Systems Inc. (NASDAQ: BASI) (”BASi” or the ”Company”) today announced that James Bourdage, Ph.D., vice president of Bioanalytical Operations, will retire as of May 4, 2018. Michael Baim, Ph.D., will assume the role of vice president of Bioanalytical Operations effective May 7, 2018.

Before joining BASi nearly four years ago, Dr. Bourdage enjoyed a long and esteemed career in the pharmaceutical industry. Having received his Ph.D. in immunochemistry from the University of Illinois, he served in leadership positions at Covance, PharmAthene, Eli Lilly and Pharmacia/Upjohn. In addition to authoring numerous scientific papers, Dr. Bourdage is a member of the American Society of Clinical Pathologists and the American Association of Pharmaceutical Scientists.

”We are grateful for Jim’s leadership, vision and commitment to BASi’s growth and success during his time with us,” said Philip Downing, senior vice president of preclinical services at BASi. ”His dedication to the BASi team, and to the clients we serve, is his legacy. We extend our best wishes to Jim and his family as he begins the next chapter in his life.”

Dr. Michael Baim is an energetic and passionate leader who brings to BASi over 30 years of experience in the pharmaceutical and lab management industries. He is well-versed in analytical methodology and project design and has a proven track record of delivering significant and sustainable profitable growth across many different business segments.

Dr. Baim received his B.A. degree in chemistry from Whitman College in Washington State. He then studied analytical chemistry as an American Chemical Society Analytical Research Fellow at Washington State University, where he earned his Ph.D. degree. He is currently working towards his MBA in marketing management.

Dr. Baim began his career at The Procter & Gamble Company in 1984 and has since held several leadership, management and technical positions at other prominent companies including Novartis and Bristol-Myers Squibb/Mead Johnson. Most recently, he served as an analytical laboratory director, designing a new analytical chemistry lab and revitalizing chemistry operations by adding new technologies and staff to optimize technical guidance and improve customer service. These efforts resulted in a sustained, double-digit growth rate for the company.

Jill Blumhoff, chief financial officer at BASi, commented, ”We are thrilled to welcome Dr. Baim to the BASi family and we are confident that his vast experience, reputation for being a thoughtful leader and mentor, and career-long focus on delivering performance to reach critical corporate goals will be a tremendous asset to our leadership team and our company. His expertise and vision align perfectly with our company’s goal to enhance and expand our bioanalytical and in-vitro bioequivalence capabilities and deliver the quality services and solutions our customers need and expect.”

About Bioanalytical Systems Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world’s leading drug development companies and medical research organizations. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.

Company Contact:

Jill Blumhoff
Chief Financial Officer &
Vice President of Finance
Phone: 765.497.8381
jblumhoff@BASinc.com

SOURCE: Bioanalytical Systems Inc.

ReleaseID: 497923

LOS ANGELES, CA / ACCESSWIRE / April 30, 2018 / Movie consumers can get a first look at the upcoming period-thriller, THE RIOT ACT with the release today of a teaser-trailer by distributor Hannover House (OTC PINK: HHSE). Inspired by true incidents occurring in Van Buren, Arkansas in 1901, the epic thriller chronicles a forbidden romance, a brutal murder and a haunting revenge. The film was directed by Devon Parks and stars Lauren Sweetser (“Winter’s Bone”) and Brett Cullen (“Dark Knight Rises,”). Hannover House plans for a nationwide USA theatrical release on August 24.

A deadly shooting is the catalyst for a brutal revenge in the period-thriller, THE RIOT ACT. Actor Brett Cullen
(“Dark Knight Returns”) portrays a troubled Opera House owner.

The teaser-trailer can be viewed at:

https://www.youtube.com/watch?v=ZCvQz_KVYz4&feature=youtu.be

International film licensors and media will be treated to a sneak-peek screening of the full feature film on May 16, during the upcoming Cannes Film Festival.

“We are so pleased with how well the film turned out,” said Eric Parkinson, Hannover House C.E.O, and Co-Executive Producer of the film. “The scope is impressive, the mood is intense and the performances are superb. We think critics and audiences are going to love the film, and we wanted to start building consumer buzz with this teaser – trailer and our sneak-peek screening of the full feature at Cannes,” he continued.

The main street of Historic Van Buren, Arkansas was converted into an old west town of 1901 in the period-thriller,
THE RIOT ACT, opening in theatres August 24.

Hannover House will present “THE RIOT ACT” in an official market screening at the Cannes Film Festival on May 16. The film’s official USA red-carpet premiere is planned for early August, ahead of the August 24 theatrical release. An official theatrical trailer is expected to be released to theatres, media journalists and broadcasters in July.

The local citizens and media of a small, Arkansas town are excited to see the traveling vaudeville troupe
that sets the stage for revenge in the period-thriller, THE RIOT ACT.

Synopsis:

1901. Two years after a quiet murder involving an out-of-town stage actor and a local doctor’s daughter, an esteemed Opera House welcomes a Vaudevillian troupe from the East for its first performances since the tragedy; and along with it, an unidentified actress with a purpose. With tensions still thick surrounding past events, this mysterious performer discovers she isn’t the only one seeking revenge: someone or something has been ”haunting” the assailant already.

Devon Parks is both the writer and director of the film. Producers are Lauren Sweetser, Jared Newman and Devon Parks; Executive Producers are Eric Parkinson and Fred Shefte. Director of Photography was Travis Joiner and Production Designer was Emily Parks. The film was shot primarily in historic Van Buren, Arkansas, including at the King Opera House. Surrounding areas Fort Smith, Springdale and Paris, AR also played home to locations for the film as well as the historic Arkansas & Missouri Railroad.

For more information please contact Desiree Garnier at 479 521 5770 desiree@HannoverHouse.com.

SOURCE: Hannover House, Inc.

ReleaseID: 498027

RADNOR, PA / ACCESSWIRE / April 30, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP alerts Aceto Corporation (NASDAQ: ACET) (“Aceto”) investors that a class action lawsuit has been filed on behalf of purchasers of Aceto common stock between August 25, 2017 and April 18, 2018, inclusive (the “Class Period”).

Investors who purchased Aceto securities during the Class Period may, no later than June 25, 2018, seek to be
appointed as a lead plaintiff representative of the class. For additional information or to
learn how to participate in this action please visit https://www.ktmc.com/new-cases/aceto-corporation#join

According to the complaint, Aceto is an international company engaged in the development, marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products.

The Class Period commences on August 25, 2017, when Aceto filed a Form 10-K with the SEC announcing the company’s financial and operating results for the fiscal fourth quarter and fiscal year ended June 30, 2017 (“2017 10-K”), which concluded that Aceto’s “internal control over financial reporting as of June 30, 2017, was effective.”

Subsequently, Aceto filed a Form 8-K with the SEC disclosing the non-reliance on its previously issued financial statements and a material weakness in internal control over financial reporting (“November 2017 8-K”).

Then, on April 18, 2018, Aceto issued a press release disclosing non-reliance on the previously issued 2018 fiscal year earnings guidance as well as the recording of non-cash intangible asset impairment charges, including goodwill, in-the range of $230-$260 million. Following this news, Aceto’s common stock declined $4.74 from a close price of $7.40 on April 18, 2018, to a close price of $2.66 on April 19, 2018.

The complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Aceto failed to implement and enforce proper internal control to identify the misapplication of cash; (ii) Aceto would incur large non-cash intangible asset impairment charges; (iii) Aceto lacked effective internal control over financial reporting; (iv) Aceto ‘s financial results for the fiscal year 2017 could not be relied upon; (v) Aceto ‘s fiscal 2018 financial guidance was overstated; and (vi) as a result of the foregoing, Aceto’s public statements were materially false and misleading at all relevant times.

Investors who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (James Maro, Jr., or Adrienne Bell, Esq.) at (888) 299-7706 or at info@ktmc.com.

Aceto investors may, no later than June 25, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP

James Maro, Jr., Esq.

Adrienne Bell, Esq.

280 King of Prussia Road

Radnor, PA 19087

(888) 299-7706

(610) 667-7706

info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 498023

RADNOR, PA / ACCESSWIRE / April 30, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP alerts Allegiant Travel Company (NASDAQ: ALGT) (“Allegiant”) investors that a class action lawsuit has been filed on behalf of purchasers of Allegiant publicly traded securities between June 8, 2015 and April 13, 2018, inclusive (the “Class Period”).

Investors who purchased Allegiant securities during the Class Period may, no later than June 25, 2018,
seek to be appointed as a lead plaintiff representative of the class. For additional information or to
learn how to participate in this action please visit https://www.ktmc.com/new-cases/allegiant-travel-company#join

According to the complaint, Allegiant focuses on the provision of travel services and products to residents of under-served cities in the United States. The company offers scheduled air transportation on limited frequency nonstop flights between under-served cities and leisure destinations.

The Class Period commences on June 8, 2015, when The Enquirer reported that the company issued a statement in connection with an Allegiant plane that was forced to make an emergency landing in Florida after smoke was detected in the cabin shortly after takeoff. The company stated afterward that the safety of its passengers and crew were its “number one priority.”

According to the complaint, on April 13, 2018, CBS News announced it would air a 60 Minutes segment on Sunday, April 15, 2018, criticizing the company’s safety and maintenance record. Following this news, shares of Allegiant fell $14.20 per share or over 8.59% to close at $151.05 per share on April 13, 2018.

Then, on April 15, 2018, CBS News aired a 60 Minutes report revealing that: (i) Allegiant aircraft had a high number of serious mechanical incidents from mid-2015 through October 2017; (ii) Allegiant lacks the infrastructure and personnel to adequately maintain their aircraft; and (iii) Allegiant has discouraged pilots from reporting safety and maintenance issues. Following this news, shares of Allegiant fell $4.65 per share or over 3% to close at $146.40 per share on April 16, 2018.

The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Allegiant lacked adequate systems to ensure its aircraft were being properly maintained; (2) consequently, Allegiant was not operating responsibly and ethically, and providing safe working conditions for its employees; and (3) as a result, the defendants’ public statements were materially false and misleading at all relevant times.

Investors who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (James Maro, Jr., or Adrienne Bell, Esq.) at (888) 299-7706 or at info@ktmc.com.

Allegiant investors may, no later than June 25, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP

James Maro, Jr., Esq.

Adrienne Bell, Esq.

280 King of Prussia Road

Radnor, PA 19087

(888) 299-7706

(610) 667-7706

info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 498024